Abstract
Erythropoietin (Epo) plays an essential role in the regulation of erythropoiesis by stimulating growth, preventing apoptosis, and promoting terminal differentiation of erythroid progenitors. The Epo receptor belongs to the cytokine receptor superfamily. Epo and its receptor have been localized to several nonhematopoietic tissues and cells, including the central and peripheral nervous systems, endothelial cells and heart. Epo exerts neuronal, vascular and cardiac protection through multiple signaling pathways in different models of tissue and cell injury in vitro and in vivo, such as ischemia, hypoxia, inflammation and oxidative stress. As a result, Epo has been suggested as a possible candidate in the treatment of neurological and cardiac disorders. A better understanding of cellular pathways and molecules modulated by Epo signaling is crucial in determining the potential therapeutic application of recombinant human Epo and may provide further insights in the development of both better synergistic therapies as well as new molecular targets. In this review, we summarize the current knowledge on the signaling pathways by which Epo offers neuroprotection and cytoprotection, signal transduction systems modulated by Epo and negative regulation of Epo signaling in the nervous system.
Keywords: Erytropoietin, erythropoietin receptor, neuroprotection, signaling pathways, cardioprotection
Current Signal Transduction Therapy
Title: Erythropoietin Signaling and Neuroprotection
Volume: 1 Issue: 2
Author(s): Sermin Genc, Mehtap Y. Egrilmez and Kursad Genc
Affiliation:
Keywords: Erytropoietin, erythropoietin receptor, neuroprotection, signaling pathways, cardioprotection
Abstract: Erythropoietin (Epo) plays an essential role in the regulation of erythropoiesis by stimulating growth, preventing apoptosis, and promoting terminal differentiation of erythroid progenitors. The Epo receptor belongs to the cytokine receptor superfamily. Epo and its receptor have been localized to several nonhematopoietic tissues and cells, including the central and peripheral nervous systems, endothelial cells and heart. Epo exerts neuronal, vascular and cardiac protection through multiple signaling pathways in different models of tissue and cell injury in vitro and in vivo, such as ischemia, hypoxia, inflammation and oxidative stress. As a result, Epo has been suggested as a possible candidate in the treatment of neurological and cardiac disorders. A better understanding of cellular pathways and molecules modulated by Epo signaling is crucial in determining the potential therapeutic application of recombinant human Epo and may provide further insights in the development of both better synergistic therapies as well as new molecular targets. In this review, we summarize the current knowledge on the signaling pathways by which Epo offers neuroprotection and cytoprotection, signal transduction systems modulated by Epo and negative regulation of Epo signaling in the nervous system.
Export Options
About this article
Cite this article as:
Genc Sermin, Egrilmez Y. Mehtap and Genc Kursad, Erythropoietin Signaling and Neuroprotection, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012002
DOI https://dx.doi.org/10.2174/157436206777012002 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Anesthetic Pharmacology for Kidney Transplantation
Current Clinical Pharmacology Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond
Current Drug Metabolism Challenges and Promises of Developing Thrombin Receptor Antagonists
Recent Patents on Cardiovascular Drug Discovery Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets